$20.090
+0.767 (+3.82%)終値時点
- 高値
- 21.770
- 始値
- 19.000
- 出来高加重平均価格
- 20.12
- 出来高
- 1.21M
- 時価総額
- —
- 安値
- 18.500
- 売買代金
- 24.25M
- EV/EBITDA（TTM）
- —
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. siRNA, or small interfering RNA, therapeutics represent a significant advancement in precision medicine by addressing diseases at the genetic level (mRNA or RNA) while avoiding permanent alterations to a patient’s genome (DNA). Its hepatic-targeted programs include Agazisiran, Onvuzosiran, and ADX-626. Its extrahepatic-targeted programs include ADX-077 and ADX-199. ADX-077 is designed to reduce body weight and fat while preserving lean mass. ADX-626, is in development for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.
AI分析 of ADARx Pharmaceuticals, Inc. (ADRX)
買いADARx Pharmaceuticals appears to be a good buy right now due to its recent IPO success, raising over $535 million, and a current price of $19.35, which is significantly below the analyst price target of $25. The stock has shown a year-to-date increase of 13.82%, reflecting strong investor confidence and market interest in its siRNA therapeutics.
イベントタイムライン
ニュース
ADRX のよくある質問 — Alphio AI が回答
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. siRNA, or small interfering RNA, therapeutics represent a significant advancement in precision medicine by addressing diseases at the genetic level (mRNA or RNA) while avoiding permanent alterations to a patient’s genome (DNA). Its hepatic-targeted programs include Agazisiran, Onvuzosiran, and ADX-626. Its extrahepatic-targeted programs include ADX-077 and ADX-199. ADX-077 is designed to reduce body weight and fat while preserving lean mass. ADX-626, is in development for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It operates in the Healthcare sector.
ADARx Pharmaceuticals appears to be a good buy right now due to its recent IPO success, raising over $535 million, and a current price of $19.35, which is significantly below the analyst price target of $25. The stock has shown a year-to-date increase of 13.82%, reflecting strong investor confidence and market interest in its siRNA therapeutics.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。